Goldman Sachs Group Inc Rani Therapeutics Holdings, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$5.07 - $6.89 $115,560 - $157,043	22,793 Added 212.25%	33,532 $173,000
Q1 2023 May 11, 2023	BUY	$5.07 - $6.89 $170,007 - $231,035	33,532 New	33,532 $173,000
Q2 2022 May 14, 2024	BUY	$8.0 - $14.25 $85,912 - $153,030	10,739 New	10,739 $111,000
Q2 2022 Aug 15, 2022	SELL	$8.0 - $14.25 $128,648 - $229,154	-16,081 Reduced 59.96%	10,739 $111,000
Q1 2022 May 16, 2022	BUY	$12.21 - $23.14 $327,472 - $620,614	26,820 New	26,820 $362,000
Q4 2021 Feb 14, 2022	SELL	$16.09 - $35.0 $975,842 - $2.12 Million	-60,649 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$10.7 - $21.43 $648,944 - $1.3 Million	60,649 New	60,649 $1.08 Million

5.77M

2.5K

2.2K

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $35.8M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.